The immunostimulant mRNA vaccine TriMix, which encodes CD70, CD40L, and a constitutively active version of TLR4, elicited robust CD8 + T cell responses in patients with stage III or IV melanoma, demonstrating favorable tumor response rates in a phase II clinical trial [62]. Here, CD8A is linked to neoplasm.